Otrivin med mentol 1 mg/ml

Otrivin is a widely recognized brand of nasal decongestant, specifically a xylometazoline-based spray used to treat nasal congestion caused by colds, hay fever, and sinusitis. The version shown, 'Otrivin med mentol', is a popular variant in the Norwegian market that includes menthol and eucalyptol to provide a cooling sensation upon application.

The brand was originally developed in Switzerland by the pharmaceutical company Ciba-Geigy (which later became part of Novartis). Over the years, the ownership of the Otrivin brand has transitioned through various corporate joint ventures. It was long part of the Novartis portfolio, then moved into a joint venture between Novartis and GlaxoSmithKline (GSK). In 2022, GSK spun off its consumer healthcare business into a new independent entity named Haleon.

As of 2026, Haleon plc remains the ultimate owner of the brand. Manufacturing for the European market, including Norway, is primarily conducted in Switzerland at specialized facilities in Nyon, though production also occurs in other global locations like Poland and Spain depending on the specific product line and regional distribution needs. In Norway, the product is typically distributed by Haleon's local subsidiary, based in Lysaker.